Support Care Cancer (2015) 23:273–282 DOI 10.1007/s00520-014-2372-3
SPECIAL ARTICLE
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines Shiying Yu & Thomas A. Burke & Alexandre Chan & Hoon-Kyo Kim & Ruey Kuen Hsieh & Xichun Hu & Jin-Tung Liang & Ana Baños & Carmel Spiteri & Dorothy M. K. Keefe
Received: 24 March 2014 / Accepted: 29 July 2014 / Published online: 13 August 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose This paper reports prescribing patterns for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries. Methods In a prospective noninterventional study, 31 sites in Australia, China, India, Singapore, South Korea, and Taiwan recorded details of CINV prophylaxis for the acute phase (first 24 h) and delayed phase (days 2–5) after single-day HEC or MEC for adult patients. Additional information on CINV prophylactic medications was collected from 6-day patient diaries. Primary antiemetic therapies were defined as corticosteroids, the 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), and neurokinin-1 receptor antagonists (NK1-RAs).
Results Evaluable patients in cycle 1 numbered 648 (318 [49 %] HEC and 330 [51 %] MEC) of mean (SD) age of 56 (12) years, including 58 % women. For the acute phase after HEC, overall (and country range), 96 % (91–100 %) of patients received a 5HT3-RA, 87 % (70–100 %) a corticosteroid, and 43 % (0–91 %) an NK1-RA. CINV prophylaxis for the HEC delayed phase was more variable: including 22 % (7–65 %) 5HT3-RA, 52 % (12–93 %) corticosteroid, and 46 % (0–88 %) NK1-RA. For the MEC acute phase, 97 % (87–100 %) of patients received 5HT3-RA and 86 % (73– 97 %) a corticosteroid. For the MEC delayed phase, 201 patients (61 %) received a primary antiemetic, including 5HT3-RA (41 %), corticosteroid (37 %), and/or NK1-RA (4 %).
Electronic supplementary material The online version of this article (doi:10.1007/s00520-014-2372-3) contains supplementary material, which is available to authorized users. S. Yu Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China T. A. Burke (*) Global Health Outcomes, Oncology, Merck Research Labs, One Merck Drive, WS2E-65, Whitehouse Station, NJ 08889, USA e-mail: [email protected] A. Chan National University of Singapore, National Cancer Centre Singapore, Singapore, Republic of Singapore H.
SPECIAL ARTICLE
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines Shiying Yu & Thomas A. Burke & Alexandre Chan & Hoon-Kyo Kim & Ruey Kuen Hsieh & Xichun Hu & Jin-Tung Liang & Ana Baños & Carmel Spiteri & Dorothy M. K. Keefe
Received: 24 March 2014 / Accepted: 29 July 2014 / Published online: 13 August 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose This paper reports prescribing patterns for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries. Methods In a prospective noninterventional study, 31 sites in Australia, China, India, Singapore, South Korea, and Taiwan recorded details of CINV prophylaxis for the acute phase (first 24 h) and delayed phase (days 2–5) after single-day HEC or MEC for adult patients. Additional information on CINV prophylactic medications was collected from 6-day patient diaries. Primary antiemetic therapies were defined as corticosteroids, the 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), and neurokinin-1 receptor antagonists (NK1-RAs).
Results Evaluable patients in cycle 1 numbered 648 (318 [49 %] HEC and 330 [51 %] MEC) of mean (SD) age of 56 (12) years, including 58 % women. For the acute phase after HEC, overall (and country range), 96 % (91–100 %) of patients received a 5HT3-RA, 87 % (70–100 %) a corticosteroid, and 43 % (0–91 %) an NK1-RA. CINV prophylaxis for the HEC delayed phase was more variable: including 22 % (7–65 %) 5HT3-RA, 52 % (12–93 %) corticosteroid, and 46 % (0–88 %) NK1-RA. For the MEC acute phase, 97 % (87–100 %) of patients received 5HT3-RA and 86 % (73– 97 %) a corticosteroid. For the MEC delayed phase, 201 patients (61 %) received a primary antiemetic, including 5HT3-RA (41 %), corticosteroid (37 %), and/or NK1-RA (4 %).
Electronic supplementary material The online version of this article (doi:10.1007/s00520-014-2372-3) contains supplementary material, which is available to authorized users. S. Yu Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China T. A. Burke (*) Global Health Outcomes, Oncology, Merck Research Labs, One Merck Drive, WS2E-65, Whitehouse Station, NJ 08889, USA e-mail: [email protected] A. Chan National University of Singapore, National Cancer Centre Singapore, Singapore, Republic of Singapore H.
